Literature DB >> 11994039

Quality-of-life assessment in osteoporosis: health-status and preference-based measures.

Anna N A Tosteson1, Cristina S Hammond.   

Abstract

Health-status and preference-based approaches to assessing health-related quality of life (HR-QOL) in osteoporosis are reviewed. Osteoporosis-targeted health-status instruments [i.e. Osteoporosis Quality-of-Life Questionnaire (OQLQ), Osteoporosis Assessment Questionnaire (OPAQ), Quality-of-Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO), Osteoporosis-Targeted Quality-of-Life Questionnaire (OPTQoL), Osteoporosis Functional Disability Questionnaire (OFDQ), Quality-of-Life Questionnaire in Osteoporosis (QUALIOST)], which have been utilised to document the adverse impact of osteoporosis on HR-QOL in diverse clinical and epidemiological studies, are described first. Preference-based approaches to osteoporosis health-outcome measurement are then considered in both clinical and health policy settings. In the clinical setting, direct preference assessments [i.e. visual analogue scale (VAS), time tradeoff (TTO), standard gamble (SG)] using either experienced or described health outcomes have consistently shown significantly lower values for osteoporosis-related health states relative to usual or ideal health. In the health-policy context, preference-classification systems [i.e. EuroQoL (EQ-5D), Health Utilities Index (HUI)] for valuing health in economic studies are reviewed. At present, there is little evidence to guide the choice of one system over another for assessing the cost effectiveness of osteoporosis interventions; however, use of a consistent set of health-state values is essential. Further research is needed to characterise associations between osteoporosis-targeted health-status instruments and preference-based health-outcome measures. In addition, the longitudinal impact of osteoporosis and related fractures on HR-QOL must be documented.

Entities:  

Mesh:

Year:  2002        PMID: 11994039     DOI: 10.2165/00019053-200220050-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  81 in total

Review 1.  Multi-attribute preference functions. Health Utilities Index.

Authors:  G W Torrance; W Furlong; D Feeny; M Boyle
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 2.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

3.  Direct clinical and welfare costs of osteoporotic fractures in elderly men and women.

Authors:  A Randell; P N Sambrook; T V Nguyen; H Lapsley; G Jones; P J Kelly; J A Eisman
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

4.  Preference for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients.

Authors:  L A Merlino; I Bagchi; T N Taylor; P Utrie; E Chrischilles; W Sumner; A Mudano; K G Saag
Journal:  Med Decis Making       Date:  2001 Mar-Apr       Impact factor: 2.583

5.  Quality of life in patients with osteoporosis fractures: cultural adaptation, reliability and validity of the Osteoporosis Assessment Questionnaire.

Authors:  F B Cantarelli; V L Szejnfeld; L M Oliveira; R M Ciconelli; M B Ferraz
Journal:  Clin Exp Rheumatol       Date:  1999 Sep-Oct       Impact factor: 4.473

6.  Functional Status Index: reliability of a chronic disease evaluation instrument.

Authors:  A M Jette
Journal:  Arch Phys Med Rehabil       Date:  1980-09       Impact factor: 3.966

7.  The Mediterranean Osteoporosis (MEDOS) Study questionnaire.

Authors:  J Dequeker; J Ranstam; J Valsson; B Sigurgevisson; E Allander
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

8.  Development of a short osteoporosis quality of life questionnaire by equating items from two existing instruments.

Authors:  X Badia; L Prieto; M Roset; A Díez-Pérez; M Herdman
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

9.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

Review 10.  Significance of osteoporosis: a growing international health care problem.

Authors:  L V Avioli
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

View more
  30 in total

1.  Simulation of the behaviour of the L1 vertebra for different material properties and loading conditions.

Authors:  Ibrahim Erdem; Eeric Truumees; Marjolein C H van der Meulen
Journal:  Comput Methods Biomech Biomed Engin       Date:  2011-12-08       Impact factor: 1.763

2.  Evaluation of trabecular microarchitecture in nonosteoporotic postmenopausal women with and without fracture.

Authors:  Richard Kijowski; Michael Tuite; Diane Kruger; Alejandro Munoz Del Rio; Michael Kleerekoper; Neil Binkley
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

3.  Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.

Authors:  T Imai; S Tanaka; K Kawakami; T Miyazaki; H Hagino; M Shiraki
Journal:  Osteoporos Int       Date:  2017-03-06       Impact factor: 4.507

4.  A longitudinal comparison of 5 preference-weighted health state classification systems in persons with intervertebral disk herniation.

Authors:  Christine M McDonough; Tor D Tosteson; Anna N A Tosteson; Alan M Jette; Margaret R Grove; James N Weinstein
Journal:  Med Decis Making       Date:  2010-11-22       Impact factor: 2.583

5.  Comparison of EQ-5D, HUI, and SF-36-derived societal health state values among spine patient outcomes research trial (SPORT) participants.

Authors:  Christine M McDonough; Margaret R Grove; Tor D Tosteson; Jon D Lurie; Alan S Hilibrand; Anna N A Tosteson
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

Review 6.  Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.

Authors:  Pierre D Delmas
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

7.  Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study.

Authors:  Luke J Peppone; Karen M Mustian; Randy N Rosier; Jennifer K Carroll; Jason Q Purnell; Michelle C Janelsins; Gary R Morrow; Supriya G Mohile
Journal:  Support Care Cancer       Date:  2013-09-17       Impact factor: 3.603

Review 8.  The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.

Authors:  L J Peppone; S Hebl; J Q Purnell; M E Reid; R N Rosier; K M Mustian; O G Palesh; A J Huston; M N Ling; G R Morrow
Journal:  Osteoporos Int       Date:  2009-12-04       Impact factor: 4.507

Review 9.  The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.

Authors:  Ted Xenodemetropoulos; Shawn Davison; George Ioannidis; Jonathan D Adachi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Quality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical vertebral fractures.

Authors:  Elisabetta Romagnoli; Vincenzo Carnevale; Italo Nofroni; Emilio D'Erasmo; Federica Paglia; Simona De Geronimo; Jessica Pepe; Natalia Raejntroph; Marianna Maranghi; Salvatore Minisola
Journal:  Osteoporos Int       Date:  2004-04-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.